Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT05922501Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2024
- Primary completion
- Dec 2028
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab, belantamab mafodotin in multiple myeloma (MM), sponsored by Massachusetts General Hospital. Started May 2024; status: recruiting.
02
Drugs
isatuximabbelantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05922501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922501.